Wednesday, 18 November 2026 Newsarchy UK live index
NewsarchyUKUK
Every UK story. Mapped, sourced, and explained where it matters.
BREAKING
World

Trump withdraws FDA nominee Heidi Overton amid Senate doubts

The White House withdrew Dr. Heidi Overton as FDA nominee as lawmakers prepared for a committee evaluation amid opposition and a lack of Senate votes.

Text:
Trump withdraws FDA nominee Heidi Overton amid Senate doubts
Trump withdraws FDA nominee Heidi Overton amid Senate doubts

The White House withdrew Dr. Heidi Overton as nominee to lead the U.S. Food and Drug Administration. According to CNBC and reports from the Associated Press, the nomination was pulled as lawmakers prepared for a decisive committee evaluation amid growing indications that the candidate lacked the necessary votes to secure Senate confirmation. Overton, a physician and White House domestic policy adviser, had spent most of her professional career working directly for Donald Trump or conservative groups aligned with his agenda. Her nomination in August was initially seen by supporters as an effort to bring a stabilizing Trump loyalist to the agency following a turbulent tenure under former commissioner Dr. Marty Makary.

Opposition to the nomination spanned across congressional lines, creating a difficult confirmation landscape. A senior administration official told Axios that the nominee lacked the required backing on Capitol Hill to proceed. To win confirmation through the Senate Health, Education, Labor and Pensions Committee, Overton would have needed the votes of all 12 Republicans on the panel, while Democrats hold 11 seats. Republican Senator Bill Cassidy of Louisiana, who chairs the health committee, had stated earlier that he remained undecided ahead of a critical vote scheduled for a Wednesday. Cassidy previously called Overton's support for breaking up combination vaccines—such as the measles, mumps, and rubella shot—almost disqualifying. Cassidy also pressed the nominee during a September hearing regarding her scientific independence and willingness to push back against Trump and Health Secretary Robert F. Kennedy Jr.

Media additions

Image via wtae.com
Image via wtae.com
Image via New York Post
Image via New York Post
Image via The Boston Globe
Image via The Boston Globe

Other Republican lawmakers raised concerns regarding additional policy stances. Senator Susan Collins of Maine questioned Overton's approach to flavored e-cigarettes, following the agency's authorization of fruit-flavored e-cigarettes for adult smokers looking to quit. Under previous administrations, including the first Trump administration, the agency had opposed vaping flavors that could attract teens and children. Meanwhile, nonpartisan campaigns surfaced around Washington, featuring protest materials targeting her positions on vaping. Anti-Overton signs appeared across Capitol Hill, including yard signs branding the nominee with critical monikers.

Democratic lawmakers also mounted strong opposition. Senator Patty Murray of Washington called Overton a far-right, anti-abortion extremist who had no business leading the agency and stated she would vote no. Critics raised alarms regarding Overton's past remarks describing the abortion pill mifepristone as dangerous to women. During hearings, Overton noted the drug was FDA-approved, having met its safety and efficacy standards, and indicated she would abide by the statutory standards set out for safety and efficacy. Erik Baptist, senior vice president of SBA Pro-Life America, issued a statement indicating his group intends to secure commitments on abortion-drug policy from whomever replaces Overton.

Internal friction within the broader administration further complicated the path forward. Influential figures within the Make America Healthy Again movement blamed her and other White House officials for sidelining some of Kennedy's top health goals, including crackdowns on food additives and pesticides. Earlier this month, Calley Means told Joe Rogan that White House aides, including Overton, worked within the administration to advance a Supreme Court decision blocking thousands of lawsuits over the weedkiller glyphosate, asserting that key decisions were carried out at the behest of industry lobbyists.

The tumultuous confirmation climate extended to other health agency picks. Trump's first nominee for the Centers for Disease Control and Prevention, Dr. David Weldon, was replaced because it was unclear he had sufficient Republican support, and two surgeon general nominees were also pulled after facing legislative pushback. Republicans had been racing to confirm Trump's nominees before handing over power to Senate Democrats in January. The FDA is currently being led on acting basis by Kyle Diamantas, an attorney and friend of Donald Trump Jr. Who was elevated to the post in May after serving as the agency's top food official. The agency has faced significant upheaval, losing about 20 percent of its employees to layoffs, buyouts, retirements or resignations since Trump took office.

Nominee / Official Agency Status
Dr. Heidi Overton FDA Nomination withdrawn by the White House
Dr. Marty Makary FDA Resigned in May
Kyle Diamantas FDA Serving as acting commissioner
Dr. David Weldon CDC Replaced due to insufficient support

Following the withdrawal, sources familiar with the discussions indicated that the White House has weighed potential alternatives, including outgoing Senator Roger Marshall of Kansas, who chairs the Senate’s Make America Healthy Again caucus and lost his reelection bid. It remained unclear when or if the administration might officially put forward another candidate.

Related stories